{"id":458520,"date":"2021-03-16T08:03:22","date_gmt":"2021-03-16T12:03:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458520"},"modified":"2021-03-16T08:03:22","modified_gmt":"2021-03-16T12:03:22","slug":"innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/","title":{"rendered":"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer"},"content":{"rendered":"
\n

ROCKVILLE, Md., March 16, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors,\u00a0today announced the appointment of Eugene (Gene) Kennedy, M.D. as Chief Medical Officer. Dr. Kennedy is an experienced biopharma executive with a track record of leadership in both industry and academia, and expertise in oncology, immuno-oncology, and clinical development.<\/p>\n

\u201cWe are thrilled to announce the addition of Gene to the ICT team during this critical time for the company,\u201d said Larry (Lei) Xiao, Ph.D., ICT\u2019s Founder and Chief Executive Officer. \u201cHis extensive experience in overseeing clinical strategy and execution will be extremely beneficial as we advance our programs into the clinic in the United States.\u201d<\/p>\n

ICT has achieved compelling clinical response data in China, with an aggregate 60% Overall Response Rate (ORR) and 20% Complete Remission (CR) rate in 10 third-line patients. The seven colorectal cancer patients (57% ORR \/ 14% CR), and the three thyroid cancer patients (67% ORR \/ 33% CR), were treated with the Company\u2019s in-house developed proprietary CoupledCAR\u00ae<\/sup> solid tumor CAR-T platform technology. ICT remains on track to submit U.S. Investigational New Drug (IND) applications in these two indications in 2021.\u00a0\u00a0<\/p>\n

\u201cWe are confident that our colorectal and thyroid cancer programs have been significantly de-risked. This confidence is based on the outcomes of our recent clinical proof-of-concept trials, which were conducted in patients who had exhausted all available treatment options, across four hospital sites through our Shanghai-based R&D center,\u201d said Dr. Xiao.<\/p>\n

Dr. Kennedy is a surgical oncologist who most recently served as Chief Medical Officer of Lumos Pharma (Lumos) and, prior to its merger with Lumos, of NewLink Genetics (NewLink). Before that, he served as NewLink\u2019s Vice President for Clinical and Medical Affairs. In these roles, Dr. Kennedy was responsible for design, implementation, and execution of all Phase 1-3 clinical trials and for overseeing medical affairs and regulatory strategy. Dr. Kennedy has filed multiple INDs for both small molecule and biologic drug candidates.<\/p>\n

Prior to joining NewLink, Dr. Kennedy had an academic career as Associate Professor of Surgery at Thomas Jefferson University in Philadelphia, Assistant Professor of Surgery at Louisiana State University in New Orleans, and Instructor of Surgery at the Johns Hopkins School of Medicine in Baltimore.<\/p>\n

Dr. Kennedy received a B.A. from the University of Virginia in Charlottesville and his M.D. from the Medical College of Virginia in Richmond. He obtained his General Surgical residency and Surgical Oncology fellowship training, along with a post-doctoral fellowship in immuno-oncology, at Johns Hopkins. He also completed additional surgical training at the Royal College of Surgeons in Ireland School of Medicine Beaumont Hospital in Dublin, Ireland.<\/p>\n

“I am extremely excited about the progress of Innovative Cellular Therapeutics\u2019 colorectal and thyroid cancer programs towards U.S. clinical trials, and about the potential of the company\u2019s CoupledCAR\u00ae<\/sup> solid tumor CAR-T platform technology in additional future indications,\u201d said Dr. Kennedy. \u201cThe responses achieved in the company\u2019s proof-of-concept trials in third-line colorectal and third-line thyroid cancer patients in China, and the extent to which these responses have already been confirmed in evaluations by top U.S. and Chinese independent third-party reviewing institutions, are remarkable and unprecedented. I am focused on bringing these revolutionary new therapies to cancer patients around the globe.”<\/p>\n

\n About Innovative Cellular Therapeutics<\/strong>
\n
Innovative Cellular Therapeutics (ICT) is a Rockville, Maryland-based clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT is in pre-Investigational New Drug (IND) discussions with the U.S. Food and Drug Administration (FDA) for its first solid tumor CAR-T programs, based on the Company\u2019s proprietary CoupledCAR\u00ae<\/sup> solid tumor CAR-T platform technology. ICT has already achieved promising responses with CoupledCAR\u00ae<\/sup> in third-line colorectal and third-line thyroid cancer patients in ongoing clinical proof-of-concept trials being conducted across multiple hospital sites in China, coordinated through the Company\u2019s Shanghai-based R&D center. ICT received its first U.S. Investigational New Drug (IND) application clearance for its ICTCAR014 program in late 2019. ICTCAR014 is based on ICT\u2019s in-house developed proprietary ArmoredCAR\u00ae<\/sup> liquid tumor CAR-T platform technology and is a next generation CD19-targeting CAR-T therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. For more information, please visit\u00a0www.ictbio.com<\/a>.<\/p>\n\n\n\n\n\n\n\n\n
\n Investor Relations Contacts:\u00a0<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Media Relations Contact:<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Morten Marott, CFO<\/td>\n\u00a0<\/td>\nKate L. Barrette<\/td>\n<\/tr>\n
Innovative Cellular Therapeutics<\/td>\n\u00a0<\/td>\nRooneyPartners LLC<\/td>\n<\/tr>\n
\n ir@ictbioinc.com<\/a>\n <\/td>\n\u00a0<\/td>\n212-223-0561<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n kbarrette@rooneyco.com<\/a>\n <\/td>\n<\/tr>\n
Irina Koffler
LifeSci Advisors
646-970-4681
ikoffler@lifesciadvisors.com<\/a><\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md., March 16, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors,\u00a0today announced the appointment of Eugene (Gene) Kennedy, M.D. as Chief Medical Officer. Dr. Kennedy is an experienced biopharma executive with a track record of leadership in both industry and academia, and expertise in oncology, immuno-oncology, and clinical development. \u201cWe are thrilled to announce the addition of Gene to the ICT team during this critical time for the company,\u201d said Larry (Lei) Xiao, Ph.D., ICT\u2019s Founder and Chief Executive Officer. \u201cHis extensive experience in overseeing clinical strategy and execution will be extremely beneficial as we advance … <\/p>\n

Continue reading “Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458520","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInnovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., March 16, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors,\u00a0today announced the appointment of Eugene (Gene) Kennedy, M.D. as Chief Medical Officer. Dr. Kennedy is an experienced biopharma executive with a track record of leadership in both industry and academia, and expertise in oncology, immuno-oncology, and clinical development. \u201cWe are thrilled to announce the addition of Gene to the ICT team during this critical time for the company,\u201d said Larry (Lei) Xiao, Ph.D., ICT\u2019s Founder and Chief Executive Officer. \u201cHis extensive experience in overseeing clinical strategy and execution will be extremely beneficial as we advance … Continue reading "Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T12:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer\",\"datePublished\":\"2021-03-16T12:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/\"},\"wordCount\":783,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/\",\"name\":\"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==\",\"datePublished\":\"2021-03-16T12:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer - Market Newsdesk","og_description":"ROCKVILLE, Md., March 16, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies with a focus on solid tumors,\u00a0today announced the appointment of Eugene (Gene) Kennedy, M.D. as Chief Medical Officer. Dr. Kennedy is an experienced biopharma executive with a track record of leadership in both industry and academia, and expertise in oncology, immuno-oncology, and clinical development. \u201cWe are thrilled to announce the addition of Gene to the ICT team during this critical time for the company,\u201d said Larry (Lei) Xiao, Ph.D., ICT\u2019s Founder and Chief Executive Officer. \u201cHis extensive experience in overseeing clinical strategy and execution will be extremely beneficial as we advance … Continue reading \"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T12:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer","datePublished":"2021-03-16T12:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/"},"wordCount":783,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/","name":"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==","datePublished":"2021-03-16T12:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDU1MyM0MDY0OTE1IzUwMDA2OTYzNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innovative-cellular-therapeutics-appoints-eugene-kennedy-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innovative Cellular Therapeutics Appoints Eugene Kennedy\u00a0as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458520"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458520\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}